CompuGroup Medical SE KGaA Valuation
Is COP2 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of COP2 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: COP2 (€14.76) is trading below our estimate of fair value (€34.22)
Significantly Below Fair Value: COP2 is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for COP2?
Key metric: As COP2 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is COP2's PE Ratio? | |
|---|---|
| PE Ratio | 30.8x |
| Earnings | €25.17m |
| Market Cap | €774.99m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.3x |
| Enterprise Value/EBITDA | 10.7x |
| PEG Ratio | 0.9x |
Price to Earnings Ratio vs Peers
How does COP2's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 54.8x | ||
EQS Equasens Société anonyme | 14.9x | 11.4% | €628.3m |
300288 Longmaster Information & Technology | 88.3x | n/a | CN¥5.4b |
HSTM HealthStream | 50.2x | 5.8% | US$979.1m |
SLP Simulations Plus | 66x | 29.3% | US$628.5m |
COP2 CompuGroup Medical SE KGaA | 30.8x | 32.9% | €775.0m |
Price-To-Earnings vs Peers: COP2 is good value based on its Price-To-Earnings Ratio (30.8x) compared to the peer average (55.4x).
Price to Earnings Ratio vs Industry
How does COP2's PE Ratio compare vs other companies in the European Healthcare Services Industry?
| 2 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 2 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: COP2 is expensive based on its Price-To-Earnings Ratio (30.8x) compared to the European Healthcare Services industry average (18.6x).
Price to Earnings Ratio vs Fair Ratio
What is COP2's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 30.8x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate COP2's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €14.76 | €26.35 +78.5% | 51.9% | €64.00 | €16.00 | n/a | 10 |
| Nov ’25 | €13.78 | €26.85 +94.8% | 50.2% | €64.00 | €16.00 | n/a | 10 |
| Oct ’25 | €14.10 | €27.25 +93.3% | 48.5% | €64.00 | €16.00 | n/a | 10 |
| Sep ’25 | €15.56 | €29.95 +92.5% | 53.3% | €64.00 | €16.00 | n/a | 10 |
| Aug ’25 | €15.90 | €29.95 +88.4% | 53.3% | €64.00 | €16.00 | n/a | 10 |
| Jul ’25 | €23.80 | €42.80 +79.8% | 29.5% | €64.00 | €31.00 | n/a | 10 |
| Jun ’25 | €27.64 | €43.20 +56.3% | 30.4% | €64.00 | €31.00 | n/a | 10 |
| May ’25 | €28.14 | €46.05 +63.6% | 25.8% | €65.00 | €32.50 | n/a | 10 |
| Apr ’25 | €28.48 | €48.45 +70.1% | 22.1% | €65.00 | €36.00 | n/a | 10 |
| Mar ’25 | €29.02 | €48.45 +67.0% | 22.1% | €65.00 | €36.00 | n/a | 10 |
| Feb ’25 | €39.68 | €54.05 +36.2% | 22.1% | €76.00 | €39.00 | n/a | 10 |
| Jan ’25 | €37.90 | €55.50 +46.4% | 20.7% | €76.00 | €41.00 | n/a | 10 |
| Dec ’24 | €35.16 | €54.91 +56.2% | 17.9% | €70.00 | €41.00 | n/a | 11 |
| Nov ’24 | €34.78 | €55.91 +60.8% | 16.2% | €70.00 | €41.00 | €13.78 | 11 |
| Oct ’24 | €37.14 | €55.91 +50.5% | 16.2% | €70.00 | €41.00 | €14.10 | 11 |
| Sep ’24 | €43.30 | €56.82 +31.2% | 15.1% | €70.00 | €41.00 | €15.56 | 11 |
| Aug ’24 | €46.20 | €57.82 +25.1% | 13.4% | €70.00 | €41.00 | €15.90 | 11 |
| Jul ’24 | €44.88 | €57.82 +28.8% | 13.4% | €70.00 | €41.00 | €23.80 | 11 |
| Jun ’24 | €50.00 | €57.41 +14.8% | 15.1% | €70.00 | €36.50 | €27.64 | 11 |
| May ’24 | €49.90 | €57.41 +15.0% | 15.1% | €70.00 | €36.50 | €28.14 | 11 |
| Apr ’24 | €47.50 | €58.14 +22.4% | 15.8% | €70.00 | €36.50 | €28.48 | 11 |
| Mar ’24 | €44.90 | €58.05 +29.3% | 16.0% | €70.00 | €36.50 | €29.02 | 11 |
| Feb ’24 | €44.56 | €57.55 +29.1% | 19.1% | €68.00 | €36.50 | €39.68 | 11 |
| Jan ’24 | €36.14 | €57.55 +59.2% | 19.9% | €68.00 | €36.50 | €37.90 | 11 |
| Dec ’23 | €37.10 | €57.50 +55.0% | 20.1% | €68.00 | €36.00 | €35.16 | 11 |
| Nov ’23 | €32.20 | €60.32 +87.3% | 20.6% | €81.00 | €37.00 | €34.78 | 11 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
Siemens Healthineers
€56.5b
Through its subsidiaries, develops, manufactures, and sells a range of diagnostic and therapeutic products and services to healthcare providers worldwide.
SHL
€50.48
7D
2.2%
1Y
-1.6%
DENTSPLY SIRONA
US$3.7b
Manufactures and sells various dental products and technologies worldwide.
XRAY
US$18.50
7D
6.2%
1Y
-35.6%
Hologic
US$18.3b
Develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment.
HOLX
US$76.50
7D
2.7%
1Y
17.5%